MODULATION OF RAS MEDIATED SIGNAL TRANSDUCTION

RAS 介导的信号转导的调节

基本信息

  • 批准号:
    2700516
  • 负责人:
  • 金额:
    $ 7.67万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1993
  • 资助国家:
    美国
  • 起止时间:
    1993-09-07 至 1999-04-30
  • 项目状态:
    已结题

项目摘要

The goal of this proposal is to analyze the mechanism by which pentoxifylline and related compounds abrogate H-ras induced aberrant signal transduction and its biological phenotype in vitro and in vivo. The different aspects of the proposal rely on preliminary evidence which demonstrates that activated H-ras(12 val) transformation upregulates the mitogenic and oncogenic phospholipids diacylglycerol(DAG) and phosphatidic acid(PA). Exposure to compounds such as pentoxifylline(PTX) inhibits the cell proliferation, colony forming capabilities and in vivo tumorigenicity associated with the transformed phenotype as well as suppressing the generation of DAG and PA by inhibiting lyso PA acyl transferase(LPAAT) and phosphatidate phosphohydrolase(PPH). This suggests specific interference with a disordered signal transduction pathway. The level at which PTX and related inhibitors of signal transduction interfere with mutant H-ras function will be examined from several perspectives. First the activation state of ras p2l in mutant and parental lines exposed to inhibitors will be examined using 32p labeling of guanine nucleotides bound to p2l followed by immunoprecipitation of p2l and thin layer chromatography of GDP/GTP. If activation state (i.e. ratio of GTP/GDP bound ras) is affected, further analysis of drug and phospholipid effects on the p2l regulators, GTPase activating and inhibiting protein, as well as rate of nucleotide exchange will be performed. The ability of LPAAT/PPH inhibitors to inhibit production of H-ras p2l will be examined by radionuclide labeling of ras p21 in conjunction with immunoprecipitation and gel electrophoresis of normal and mutant protein. The potential for these compounds to affect subcellular localization of ras p21 will be studied by radionuclide labeling, differential centrifugation and immunoprecipitation. If localization of p2l ras is affected , analysis of ras isoprenylation in the presence of LPAAT and PPH inhibitors will be carried out. Downstream effects of inhibitors on H-ras mediated signal transduction will be analyzed by quantitating phosphorylation of artificial substrates by MAP kinase, S6 kinase, CAM kinase and Protein Kinase C. The necessity for normal and mutant H-ras in the signal transduction process will be analyzed by eliminating production of normal, and activated p2l ras using specific antisense oligonucleotides. The response profile of signaling phospholipids on HPLC after stimulation with different agonists will then be examined and compared with signaling seen with intact ras.The specificity of PTX and LPAAT/PPH inhibitor effects on ras modulation of signal transduction and tumorogenictiy will be compared with effects on other families of oncogenes which affect signal transduction. These effects will be analyzed by quantitation of cell proliferation, colony forming capability and phospholipid levels in fibroblasts transformed with these activated oncogenes. This comparison will allow definition of the ubiquity of the aberrant signal transduction system that we have defined in H-ras(12 val) transformed fibroblasts and potentially the role which normal ras plays in tumorigenicity induced by these oncogenes.
本提案的目的是分析 喷替福林和相关化合物消除H-ras诱导的异常 信号转导及其生物学表型。的 该提案的不同方面依赖于初步证据, 表明激活的H-ras(12瓦尔)转化上调了 促有丝分裂和致癌磷脂二酰基甘油(DAG)和磷脂 酸(PA)。暴露于化合物如戊茶碱(PTX)抑制了 细胞增殖、集落形成能力和体内致瘤性 与转化的表型相关,以及抑制 通过抑制溶血PA酰基转移酶(LPAAT)产生DAG和PA, 磷脂酸磷酸水解酶(PPH)。这表明特定的干扰 信号转导通路紊乱PTX和 相关信号转导抑制剂干扰突变型H-ras 将从几个角度来审查功能。首先是激活 暴露于抑制剂突变株和亲本株中的rasp 2l状态将 使用结合到p2 l的鸟嘌呤核苷酸的32 p标记进行检查 然后进行p2 l的免疫沉淀和 国内生产总值/GTP。如果激活状态(即GTP/GDP结合ras的比率)为 受影响,进一步分析药物和磷脂对p2 l的影响 调节剂,GT3激活和抑制蛋白,以及 将进行核苷酸交换。LPAAT/PPH抑制剂 用放射性核素法检测H-ras p2 l的抑制作用 rasp 21标记结合免疫沉淀和凝胶 正常蛋白和突变蛋白的电泳。这些的潜力 影响rasp 21亚细胞定位的化合物将通过以下方法进行研究: 放射性核素标记、差速离心和 免疫沉淀。如果p2 l ras的定位受到影响, 在LPAAT和PPH抑制剂的存在下,ras异戊二烯化将被抑制。 贯彻抑制剂对H-ras介导信号的下游影响 转导将通过定量磷酸化来分析, MAP激酶、S6激酶、CAM激酶和蛋白质的人工底物 激酶C正常和突变型H-ras在信号中的必要性 将通过消除正常, 并使用特异性反义寡核苷酸激活p2 L-ras。的 用以下物质刺激后,信号传导磷脂在HPLC上的响应曲线 然后检查不同的激动剂并与所见的信号传导进行比较 PTX和LPAAT/PPH抑制剂的特异性作用, ras对信号转导的调节与肿瘤发生的关系 对其他影响信号传导的癌基因家族有影响 转导这些影响将通过定量细胞 增殖,集落形成能力和磷脂水平, 成纤维细胞转化这些激活的癌基因。该比较 将允许定义异常信号转导的普遍性 我们已经在H-ras(12瓦尔)转化的成纤维细胞中定义了该系统, 可能正常ras在肿瘤诱导中的作用 这些致癌基因。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Epidermal growth factor receptor stimulation of diacylglycerol kinase.
表皮生长因子受体刺激二酰甘油激酶。
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bruce Montgomery其他文献

Bruce Montgomery的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Bruce Montgomery', 18)}}的其他基金

High-dose Testosterone in Men with Metastatic Castration-resistant Prostate Cancer and ATM or CDK12 deficiency
高剂量睾酮治疗患有转移性去势抵抗性前列腺癌且 ATM 或 CDK12 缺乏症的男性
  • 批准号:
    10260977
  • 财政年份:
    2021
  • 资助金额:
    $ 7.67万
  • 项目类别:
High-dose Testosterone in Men with Metastatic Castration-resistant Prostate Cancer and ATM or CDK12 deficiency
高剂量睾酮治疗患有转移性去势抵抗性前列腺癌且 ATM 或 CDK12 缺乏症的男性
  • 批准号:
    10426250
  • 财政年份:
    2021
  • 资助金额:
    $ 7.67万
  • 项目类别:
Carboplatin or Olaparib for BRcA deficient prostate cancer (COBRA)
卡铂或奥拉帕尼治疗 BRcA 缺陷型前列腺癌 (COBRA)
  • 批准号:
    10578711
  • 财政年份:
    2020
  • 资助金额:
    $ 7.67万
  • 项目类别:
Carboplatin or Olaparib for BRcA deficient prostate cancer (COBRA)
卡铂或奥拉帕尼治疗 BRcA 缺陷型前列腺癌 (COBRA)
  • 批准号:
    10417024
  • 财政年份:
    2020
  • 资助金额:
    $ 7.67万
  • 项目类别:
EGFR VACCINE TRIAL
EGFR 疫苗试验
  • 批准号:
    7603433
  • 财政年份:
    2007
  • 资助金额:
    $ 7.67万
  • 项目类别:
A PHASE I STUDY OF AN EGFRVIII PEPTIDE-BASED VACCINE IN PATIENTS WITH CANCER
基于 EGFRVIII 肽的疫苗对癌症患者的 I 期研究
  • 批准号:
    7379316
  • 财政年份:
    2006
  • 资助金额:
    $ 7.67万
  • 项目类别:
A PHASE I STUDY OF AN EGFRVIII PEPTIDE BASE VACCINE IN PATIENTS WITH CANCER
EGFRVIII 肽基疫苗针对癌症患者的 I 期研究
  • 批准号:
    7198814
  • 财政年份:
    2005
  • 资助金额:
    $ 7.67万
  • 项目类别:
A phase I study of an EGFRvIII peptide base vaccine in patients with cancer
EGFRvIII 肽基疫苗在癌症患者中的 I 期研究
  • 批准号:
    6974523
  • 财政年份:
    2004
  • 资助金额:
    $ 7.67万
  • 项目类别:
PHASE I TRIAL OF A PEPTIDE VACCINE AGAINST EGFRVIII
针对 EGFRVIII 的肽疫苗的 I 期试验
  • 批准号:
    2893240
  • 财政年份:
    1999
  • 资助金额:
    $ 7.67万
  • 项目类别:
PHASE I TRIAL OF A PEPTIDE VACCINE AGAINST EGFRVIII
针对 EGFRVIII 的肽疫苗的 I 期试验
  • 批准号:
    6377396
  • 财政年份:
    1999
  • 资助金额:
    $ 7.67万
  • 项目类别:

相似海外基金

The analysis of proteinuria caused by antineoplastics and the preventative effects with antihypertensive medications using the Japanese medical database
利用日本医学数据库分析抗肿瘤药物引起的蛋白尿及抗高血压药物的预防效果
  • 批准号:
    21K17258
  • 财政年份:
    2021
  • 资助金额:
    $ 7.67万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Expediting Drug Development by Profiling Novel Antineoplastics by Mass Spectrometry-based Biomarker Profiling
通过基于质谱的生物标志物分析来分析新型抗肿瘤药物,加速药物开发
  • 批准号:
    499958-2016
  • 财政年份:
    2016
  • 资助金额:
    $ 7.67万
  • 项目类别:
    Engage Grants Program
Combinatorial Peptidomimetics as Antineoplastics
作为抗肿瘤药的组合肽模拟物
  • 批准号:
    6623455
  • 财政年份:
    2002
  • 资助金额:
    $ 7.67万
  • 项目类别:
Combinatorial Peptidomimetics as Antineoplastics
作为抗肿瘤药的组合肽模拟物
  • 批准号:
    6465958
  • 财政年份:
    2002
  • 资助金额:
    $ 7.67万
  • 项目类别:
Novel Nanoparticle Delivery System for Antineoplastics
新型抗肿瘤纳米颗粒输送系统
  • 批准号:
    6483914
  • 财政年份:
    2002
  • 资助金额:
    $ 7.67万
  • 项目类别:
GLYCOLIPIDS AND CYTOTOXIC RESPONSE TO ANTINEOPLASTICS
糖脂和抗肿瘤药物的细胞毒性反应
  • 批准号:
    6124630
  • 财政年份:
    1998
  • 资助金额:
    $ 7.67万
  • 项目类别:
GLYCOLIPIDS AND CYTOTOXIC RESPONSE TO ANTINEOPLASTICS
糖脂和抗肿瘤药物的细胞毒性反应
  • 批准号:
    6329037
  • 财政年份:
    1998
  • 资助金额:
    $ 7.67万
  • 项目类别:
GLYCOLIPIDS AND CYTOTOXIC RESPONSE TO ANTINEOPLASTICS
糖脂和抗肿瘤药物的细胞毒性反应
  • 批准号:
    2747737
  • 财政年份:
    1998
  • 资助金额:
    $ 7.67万
  • 项目类别:
POLYMORPHIC METABOLISM OF ANTINEOPLASTICS IN CHILDREN
儿童抗肿瘤药物的多态性代谢
  • 批准号:
    3459680
  • 财政年份:
    1990
  • 资助金额:
    $ 7.67万
  • 项目类别:
POLYMORPHIC METABOLISM OF ANTINEOPLASTICS IN CHILDREN
儿童抗肿瘤药物的多态性代谢
  • 批准号:
    3459678
  • 财政年份:
    1990
  • 资助金额:
    $ 7.67万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了